

RECORDATI: ORDINARY GENERAL MEETING OF SHAREHOLDERS CONVENED FOR 21 APRIL 2023, IN A SINGLE CALL. DOCUMENTS RELATING TO THE GENERAL MEETING.

Milan, 10 March 2023 – The Board of Directors of Recordati S.p.A., meeting under the chairmanship of Andrea Recordati, resolved to convene the Annual Shareholders’ Meeting to be held on 21st April 2023 at 9.00 am, in a single call – in the manner expressly specified in the notice of call to which reference is made - with the following agenda:

1. Board of Directors’ Review of Operations; Report of the Board of Statutory Auditors; Financial Statements as at and for the financial year ended 31st December 2022; related and consequent resolutions:
 - a) Financial Statements as at 31st December 2022;
 - b) allocation of the profit for the 2022 financial year.
2. Appointment of the Board of Statutory Auditors:
 - a) appointment of the members of the Board of Statutory Auditors;
 - b) appointment of the Chair of the Board of Statutory Auditors;
 - c) determination of their remuneration.
3. Report on the remuneration policy and the remuneration paid pursuant to article 123-ter, paragraphs 3-bis and 6, of Legislative Decree no. 58 of 24th February 1998:
 - a) binding resolution on the first section regarding the remuneration policy;
 - b) non-binding resolution on the second section on the remuneration paid for 2022.
4. Approval of the long-term incentive plan based on financial instruments named “2023-2025 Performance Shares Plan”, upon withdrawal of the “2021-2023 Stock Option Plan” concerning the grant of stock options scheduled for 2023; related and consequent resolutions in accordance with article 114-bis of Legislative Decree no. 58 of 24th February 1998.
5. Proposal to authorise the purchase and utilisation of treasury stock; related and consequent resolutions.

The entire notice of call of the Ordinary General Meeting of the Shareholders will be made publicly as of today at the Company’s registered office, on the Company’s website ¹ and on the authorized storage system 1Info (www.1Info.it).

In particular, it is noted that Recordati² has decided to make use of the faculty to provide for the participation of the shareholders in the General Meeting exclusively through the Designated Representative by the Company pursuant to art. 135-undecies of the Legislative Decree 58/98, without physical participation on their part. Information on participating by proxy is available in the notice of call to which reference is made.

¹ (<https://www.recordati.it/en/investors/shareholders-meetings/>)

² In accordance with the provisions of art. 106 of the Italian Law Decree no. 18/2020, converted by Italian Law no. 27/2020 (the Decree) and as further extended by article 3, paragraph 10-undecies, of Italian Law Decree no. 198 of 29 December 2022, converted by Italian Law no. 14 of 24 February 2023.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered office
VIA M. CIVITALI, 1
20148 MILAN, ITALY
TEL. +39 0248787.1
FAX +39 0240073747

SHARE CAPITAL € 26,140,644.50 fully paid up
BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI
00748210150
TAX CODE/VAT NO. 00748210150

Company subject to management and coordination by Rossini Luxembourg S.à.r.l

Furthermore, today the Board of Directors of Recordati S.p.A. has approved **the Directors' Report on the appointment of the Board of Statutory Auditors**, including the proposed resolution to be submitted to the Ordinary General Meeting of the Shareholders.

It should be noted that the appointment will be performed on a slate basis – and the percentage of capital required for the presentation of slates is equal to 1% of the share capital with voting right at the Ordinary General Meeting of the Shareholders – pursuant to art. 26 of the company by-laws and the applicable laws and regulations in force. Further information is made available to shareholders in the above mentioned Directors' Report which will be made available, as of today, at the Company's registered office, on the Company website (www.recordati.it, section Investors, Shareholders' Meeting) and on the authorized storage system 1Info (www.1Info.it).

In relation to the further deliberation proposals to be submitted to the Ordinary General Meeting of the Shareholders, the Board of Directors plans to examine and approve them during the next meeting scheduled for 16th March 2023. Within the terms prescribed by current laws and regulations, additional Directors' reports on the items of the Shareholders' Meeting agenda and any further documentation related to these items will then be made available at the Company's registered office, on Company's website and on the authorized storage system 1Info (www.1Info.it).

Recordati (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a specialised business dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2021 was €1,580.1 million, operating income was €490.2 million and net income was €386.0 million.

Further information:

Recordati website: www.recordati.it

Investor Relations

Federica De Medici

(39) 02 48787146

email: investorelations@recordati.it

Investor Relations

Lucia Abbatantuoni

(39) 02 48787213

e-mail: investorelations@recordati.it

Press Office

Brunswick: Barbara Scalchi / Andrea Mormandi

(39) 02 9288 6200

e-mail: recordati@brunswickgroup.com